(62 days)
No
The summary describes a physical implant and its materials, with performance studies based on mechanical analysis (FEA, cross-sectional area). There is no mention of software, algorithms, or any technology related to AI or ML.
No.
The device is an implant for spinal fusion and is not described as providing therapy. Its purpose is mechanical stabilization and support for fusion, not active therapeutic intervention.
No
The device is an implantable system for spinal fusion, designed to treat degenerative disc disease. It is used in surgical procedures and does not perform any diagnostic functions like analyzing patient data to identify conditions.
No
The device description explicitly states that the device components are made of polyetheretherketone (PEEK) and contain tantalum markers, indicating it is a physical implant and not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening.
- Device Description and Intended Use: The provided text clearly describes a surgical implant (a lumbar interbody fusion system) used to fuse vertebrae in the spine. It is implanted directly into the body during surgery.
- Lack of Specimen Analysis: There is no mention of this device being used to analyze any biological specimens. Its function is structural support and facilitating bone fusion within the body.
Therefore, based on the provided information, the Genesys Spine Apache™ Lateral Lumbar Interbody Fusion System is a surgical implant, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Genesys Spine Apache™ Lateral Lumbar Interbody Fusion System is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion.
Product codes
MAX
Device Description
The intent of this Special 510(k) is to add new components to the currently cleared Genesys Spine Apache® Lateral Lumbar Interbody Fusion System (K130913). This submission will offer various device configurations based on surgical approach and patient anatomy, and consist of a Genesys Spine Lumbar Interbody Fusion Device, which may be implanted as a single device via a lateral approach.
The Genesys Spine Apache® Lateral Lumbar Interbody Fusion System is comprised of various device configurations designed to accommodate patient anatomy and provide the surgeon with different surgical approach options.
The Genesys Spine Apache® Lateral Lumbar Interbody Fusion System implant components are made of polyetheretherketone (Invibio PEEK Optima LT1) that conforms to ASTM F2026. Additionally, the devices contain tantalum markers (ASTM F560) to assist the surgeon with proper placement of the device. The additional implant offering being proposed has similar technological characteristics and identical indications as the currently cleared product line.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
lumbar spine, from L2 to S1
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Cross-sectional area analysis. Finite Element Analysis (FEA), and projected area calculations demonstrated substantial equivalence to the predicate devices. The crosssectional area analysis was used to determine the potential worst-case implant. A validated compressive FEA model was then used to determine the von Mises stresses. The maximum von Mises stress values were substantially lower in the subject device than the predicate device. Projected area calculations were used to determine if a new worst case was created for expulsion or subsidence. All of the performance data suggested that a new worst case was not created and that the subject device is substantially equivalent in the evaluated areas.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Genesys Spine Apache® Lateral Lumbar Interbody Fusion System (K130913), Genesys Spine Interbody Fusion System (K103034), Medtronic Capstone Control Spinal System (K120368), Cogent Spine Lateral Interbody System (K151406)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is an abstract symbol that resembles a stylized human figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 21, 2016
Genesys Spine Mr. Dave Lamb Vice President of Compliance 1250 Capitol of Texas Highway South Building Three. Suite 600 Austin, Texas 78746
Re: K161404
Trade/Device Name: Genesys Spine Apache® Lateral Lumbar Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: June 28, 2016 Received: June 30, 2016
Dear Mr. Lamb:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K161404
K161404 Page 1 of 1
Device Name
GENESYS SPINE APACHE® LATERAL LUMBAR INTERBODY FUSION SYSTEM
Indications for Use (Describe)
The Genesys Spine Apache™ Lateral Lumbar Interbody Fusion System is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
| Submitter's Name: | Genesys Spine |
|---|---|
| Submitter's Address: | 1250 Capital of Texas Highway South |
| Building Three, Suite 600 | |
| Austin, Texas 78746 | |
| Submitter's Telephone: | 512-381-7093 |
| Submitter's Fax: | 800-817-4938 |
| Contact Name: | Ben Keller |
| Date Summary was | |
| Prepared: | May 19th, 2016 |
| Trade or Proprietary Name: | Genesys Spine Apache® Lateral Lumbar Interbody |
| Fusion System | |
| Common or Usual Name: | Intervertebral Fusion Device |
| Classification: | Class II per 21 CFR §888.3080 |
| Product Codes: | MAX |
| Classification Panel: | Orthopedic and Rehabilitation Devices Panel |
| Primary Predicate Device: | Genesys Spine Apache® Lateral Lumbar Interbody |
| Fusion System (K130913) | |
| Additional Predicate | |
| Devices: | - Genesys Spine Interbody Fusion System (K103034) |
- Medtronic Capstone Control Spinal System
(K120368) - Cogent Spine Lateral Interbody System (K151406) |
DESCRIPTION OF THE DEVICE SUBJECT TO PREMARKET NOTIFICATION:
The intent of this Special 510(k) is to add new components to the currently cleared Genesys Spine Apache® Lateral Lumbar Interbody Fusion System (K130913). This submission will offer various device configurations based on surgical approach and patient anatomy, and consist of a Genesys Spine Lumbar Interbody Fusion Device, which may be implanted as a single device via a lateral approach.
INDICATIONS FOR USE
The Genesys Spine Apache® Lateral Lumbar Interbody Fusion System is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion.
4
TECHNICAL CHARACTERISTICS
The Genesys Spine Apache® Lateral Lumbar Interbody Fusion System is comprised of various device configurations designed to accommodate patient anatomy and provide the surgeon with different surgical approach options.
The Genesys Spine Apache® Lateral Lumbar Interbody Fusion System implant components are made of polyetheretherketone (Invibio PEEK Optima LT1) that conforms to ASTM F2026. Additionally, the devices contain tantalum markers (ASTM F560) to assist the surgeon with proper placement of the device. The additional implant offering being proposed has similar technological characteristics and identical indications as the currently cleared product line.
PERFORMANCE DATA
Cross-sectional area analysis. Finite Element Analysis (FEA), and projected area calculations demonstrated substantial equivalence to the predicate devices. The crosssectional area analysis was used to determine the potential worst-case implant. A validated compressive FEA model was then used to determine the von Mises stresses. The maximum von Mises stress values were substantially lower in the subject device than the predicate device. Projected area calculations were used to determine if a new worst case was created for expulsion or subsidence. All of the performance data suggested that a new worst case was not created and that the subject device is substantially equivalent in the evaluated areas.
CONCLUSION
The overall technology characteristics and mechanical performance data lead to the conclusion that Genesys Spine Apache® Lateral Lumbar Interbody Fusion System is substantially equivalent to the Genesys Spine Apache® Lateral Lumbar Interbody Fusion System, Genesys Spine Interbody Fusion System, Medtronic Capstone Control Spinal System, and Cogent Spine Lateral Interbody System.